Juan Andres - Mar 1, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Mar 1, 2022
Transactions value $
-$271,560
Form type
4
Date filed
3/3/2022, 03:53 PM
Previous filing
Mar 2, 2022
Next filing
Mar 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $28.4K +2K +22.05% $14.22* 11.1K Mar 2, 2022 Direct F1
transaction MRNA Common Stock Sale -$300K -2K -18.07% $150.00 9.07K Mar 2, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Award $0 +32.5K $0.00 32.5K Mar 1, 2022 Common Stock 32.5K $149.52 Direct F2
transaction MRNA Restricted Stock Units Award $0 +8.02K $0.00 8.02K Mar 1, 2022 Common Stock 8.02K $0.00 Direct F3
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -2K -9.7% $0.00 18.6K Mar 2, 2022 Common Stock 2K $14.22 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021.
F2 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer